

Câncer de Vias Biliares

Gencitabina

Gencitabina: 1000mg/m² IV D1,8,15 , a cada 28 dias Ref.(1)

Cisplatina + Gencitabina

Cisplatina: 60mg/m² IV D1

Gencitabina: 1250mg/m² IV D1 e D8

a cada 21 dias

Ref.(2)

GEMOX

Oxaliplatina: 100mg/m² IV D1

Gencitabina: 1000mg/m² IV D1

a cada 14 dias

Ref. (3)

GEMCAP

Gencitabina: 1000mg/m² IV D1 e D8

Capecitabina: 1300mg/m²/dia VO D1 a D14

a cada 21 dias

Ref. (4)

Capecitabina + Cisplatina

Capecitabina: 1250mg/m² VO BID por 14 dias

Cisplatina: 60mg/m² IV D1

a cada 3 semanas

Ref.(5)

Mitomicina + 5-Fluorouracil + Leucovorin

Mitomicina C: 10mg/m² IV D1

5-Fluorouracil: 350mg/m² IV D1 a D4

Leucovorin: 350mg/m² IV D1 a D4

a cada 4 semanas

Ref. (6)

5-Fluorouracil + Radioterapia

5-Fluorouracil: 500mg/m² do D1 a D3 IV pulso na 1° e 5° semana da radioterapia

OU

5-Fluorouracil: 400mg/m² e Leucovorin: 20mg/m², ambos do D1 a D4 em pulso na 1° e 5° semana da radioterapia

Radioterapia: concomitante ao 5-Fluorouracil na dose de 45 Gy em frações de 180cGy + boost de 5,4-9,0Gy (dose total 54Gy).
Ref. (7)

Capecitabina + Radioterapia (M. D. Anderson)

Capecitabina: 1500mg/m²/dia VO duas vezes ao dia de segunda a sexta-feira durante todo o tratamento radioterápico.

Radioterapia: concomitante a capecitabina na dose de 45 Gy com boost de 10Gy. Ref. (8)

CAPOX

Oxaliplatina: 130mg/m² IV em 2 horas no D1

Capecitabina: 1000mg/m² VO duas vezes ao dia do D1 ao D14 a cada 21 dias Ref. (9)

1. Gebbia V *et al.* Treatment of Inoperable and/or Metastatic Biliary Tree Carcinomas With Single-Agent Gemcitabine or in Combination With Levofolinic Acid and Infusional Fluorouracil: Results of a Multicenter Phase II Study. *J Clin Oncol*, 2001; 19: 4089-91.
2. Kim ST *et al.* A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. *Cancer*, 2006: 106:1339-46

3. Andre T, *et al.* Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. *Ann Oncol.* 2004; 15: 1339-43.
4. Knox JJ *et al.* Combining Gemcitabine and Capecitabine in Patients With Advanced Biliary Cancer: A Phase II Trial. *J Clin Oncol.* 2005; 23:2332-8.
5. Kim TW, Chang HM, Kang HJ, Lee JR, Ryu MH, Ahn JH, Kim JH, Lee JS, Kang YK. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. *Ann Oncol.* 2003 Jul;14(7):1115-20.
6. Polyzos A, Nikou G, Giannopoulos A *et al.* Chemotherapy of biliary tract cancer with mitomycin-C and 5-fluorouracil biologically modulated by folinic acid. A phase II study. *Ann Oncol.* 1996 Aug;7(6):644-5.
7. Kresl JJ, Schild SE, Henning GT, Gunderson LL, Donohue J, Pitot H, Haddock MG, Nagorney D. Adjuvant external beam radiation therapy with concurrent chemotherapy in the management of gallbladder carcinoma. *Int J Radiat Oncol Biol Phys* 2002; 52: 167.
8. Borghero Y, Crane, CH, Szklaruk J, Oyarzo M, *et al.* Extrahepatic Bile Duct Adenocarcinoma: Patients at High-Risk for Local Recurrence Treated with Surgery and Adjuvant Chemoradiation Have an Equivalent Overall Survival to Patients with Standard-Risk Treated with Surgery Alone. *Annals of Surgical Oncology.* 2008; 15(11):3147-3156.
9. Capecitabine plus oxaliplatin as First-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. *Br J Cancer* 2008; 98: 309-315.